-
Je něco špatně v tomto záznamu ?
The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study
O. Kalita, Z. Sporikova, M. Hajduch, M. Megova Houdova, R. Slavkovsky, L. Hrabalek, M. Halaj, Y. Klementova, M. Dolezel, J. Drabek, L. Tuckova, J. Ehrmann, J. Vrbkova, R. Trojanec, M. Vaverka
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem
Free Medical Journals od 2006
PubMed Central od 2006
Europe PubMed Central od 2006
Open Access Digital Library od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources od 2005
Odkazy
PubMed
33801093
DOI
10.3390/curroncol28020122
Knihovny.cz E-zdroje
- MeSH
- DNA modifikační methylasy genetika MeSH
- glioblastom * genetika terapie MeSH
- isocitrátdehydrogenasa genetika MeSH
- lidé MeSH
- metylace DNA MeSH
- mutace MeSH
- nádory mozku * genetika terapie MeSH
- prospektivní studie MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
This prospective population-based study on a group of 132 resected IDH-wildtype (IDH-wt) glioblastoma (GBM) patients assesses the prognostic and predictive value of selected genetic biomarkers and clinical factors for GBM as well as the dependence of these values on the applied therapeutic modalities. The patients were treated in our hospital between June 2006 and June 2015. Clinical data and tumor samples were analyzed to determine the frequencies of TP53, MDM2, EGFR, RB1, BCR, and CCND1 gene aberrations and the duplication/deletion statuses of the 9p21.3, 1p36.3, 19q13.32, and 10p11.1 chromosome regions. Cut-off values distinguishing low (LCN) and high (HCN) copy number status for each marker were defined. Additionally, MGMT promoter methylation and IDH1/2 mutation status were investigated retrospectively. Young age, female gender, Karnofsky scores (KS) above 80, chemoradiotherapy, TP53 HCN, and CCND1 HCN were identified as positive prognostic factors, and smoking was identified as a negative prognostic factor. Cox proportional regression models of the chemoradiotherapy patient group revealed TP53 HCN and CCND1 HCN to be positive prognostic factors for both progression-free survival and overall survival. These results confirmed the influence of key clinical factors (age, KS, adjuvant oncotherapy, and smoking) on survival in GBM IDH-wt patients and demonstrated the prognostic and/or predictive importance of CCND1, MDM2, and 22q12.2 aberrations.
Department of Neurosurgery University Hospital Olomouc 1 P Pavlova 6 779 00 Olomouc Czech Republic
Department of Oncology University Hospital Olomouc 1 P Pavlova 6 779 00 Olomouc Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025950
- 003
- CZ-PrNML
- 005
- 20211026133341.0
- 007
- ta
- 008
- 211013s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/curroncol28020122 $2 doi
- 035 __
- $a (PubMed)33801093
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kalita, Ondrej $u Department of Neurosurgery, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 245 14
- $a The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study / $c O. Kalita, Z. Sporikova, M. Hajduch, M. Megova Houdova, R. Slavkovsky, L. Hrabalek, M. Halaj, Y. Klementova, M. Dolezel, J. Drabek, L. Tuckova, J. Ehrmann, J. Vrbkova, R. Trojanec, M. Vaverka
- 520 9_
- $a This prospective population-based study on a group of 132 resected IDH-wildtype (IDH-wt) glioblastoma (GBM) patients assesses the prognostic and predictive value of selected genetic biomarkers and clinical factors for GBM as well as the dependence of these values on the applied therapeutic modalities. The patients were treated in our hospital between June 2006 and June 2015. Clinical data and tumor samples were analyzed to determine the frequencies of TP53, MDM2, EGFR, RB1, BCR, and CCND1 gene aberrations and the duplication/deletion statuses of the 9p21.3, 1p36.3, 19q13.32, and 10p11.1 chromosome regions. Cut-off values distinguishing low (LCN) and high (HCN) copy number status for each marker were defined. Additionally, MGMT promoter methylation and IDH1/2 mutation status were investigated retrospectively. Young age, female gender, Karnofsky scores (KS) above 80, chemoradiotherapy, TP53 HCN, and CCND1 HCN were identified as positive prognostic factors, and smoking was identified as a negative prognostic factor. Cox proportional regression models of the chemoradiotherapy patient group revealed TP53 HCN and CCND1 HCN to be positive prognostic factors for both progression-free survival and overall survival. These results confirmed the influence of key clinical factors (age, KS, adjuvant oncotherapy, and smoking) on survival in GBM IDH-wt patients and demonstrated the prognostic and/or predictive importance of CCND1, MDM2, and 22q12.2 aberrations.
- 650 12
- $a nádory mozku $x genetika $x terapie $7 D001932
- 650 _2
- $a metylace DNA $7 D019175
- 650 _2
- $a DNA modifikační methylasy $x genetika $7 D015254
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a glioblastom $x genetika $x terapie $7 D005909
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a isocitrátdehydrogenasa $x genetika $7 D007521
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sporikova, Zuzana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Megova Houdova, Magdalena $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Slavkovsky, Rastislav $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Hrabalek, Lumir $u Department of Neurosurgery, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Halaj, Matej $u Department of Neurosurgery, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Klementova, Yvona $u Department of Oncology, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Dolezel, Martin $u Department of Oncology, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Drabek, Jiri $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Tuckova, Lucie $u Department of Pathology and Laboratory of Molecular Pathology, University Hospital Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Ehrmann, Jiri $u Department of Pathology and Laboratory of Molecular Pathology, University Hospital Olomouc, Hnevotinska 3, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Vrbkova, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Trojanec, Radek $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University in Olomouc, Hnevotinska 5, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Vaverka, Miroslav $u Department of Neurosurgery, University Hospital Olomouc, I.P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 773 0_
- $w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 28, č. 2 (2021), s. 1280-1293
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33801093 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133347 $b ABA008
- 999 __
- $a ok $b bmc $g 1714841 $s 1146457
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 28 $c 2 $d 1280-1293 $e 20210321 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
- LZP __
- $a Pubmed-20211013